Case Study

Biotech Corp Accelerates FDA GxP Platform Clearance with Continuous Proofing

How a clinical-stage manufacturer replaced retrospective validation binders with evidence generated at build time, and walked into an FDA inspection with proof that was already current.

7 Months

Removed From Platform Clearance Timeline

100%

GxP Pipelines Under Live Validation

Zero

Deviations Raised at Inspection

3,400+

Validation Artefacts Generated Automatically

Client Profile

Company: Biotech Corp
Industry: Healthcare & Life Sciences
Company Size: 1,200+ Employees
Location: Basel, Switzerland
Engine Deployed: Zelar Trust AI Engine V4

The Challenge

Validation evidence that was always describing a system as it used to be.

Biotech Corp's manufacturing and laboratory platforms fell under GxP, and every release required a validation pack: installation qualification, operational qualification, and performance qualification, assembled by quality engineers reading the system and writing down what they found. A pack took roughly six weeks to build.

Because the pack was assembled after the fact, it described the platform at the moment someone happened to look. Any configuration change between assembly and review reopened the question, and reviewers had no way to distinguish a document that was still accurate from one that had quietly gone stale.

The consequence was cadence. Releases were spaced to fit the validation effort rather than the science, and 21 CFR Part 11 audit trail requirements were satisfied by exporting logs into static evidence that had to be re-exported the moment anyone asked a follow-up question.

The Solution

Zelar Trust attached to the build and deployment pipeline behind every GxP-regulated system, so qualification evidence is produced as a by-product of the release itself. Each deployment emits its own installation and operational qualification record, signed against the exact artefact that shipped and stored immutably.

Performance qualification moved onto continuous monitoring rather than a scheduled campaign. The platform proves its own operating envelope constantly, and quality engineers review exceptions and sign the record instead of reconstructing it — the judgement stays human, the transcription does not.

Validation Evidence Effort per Release

Before Zelar (6-Week Manual Validation Pack)

With Zelar (Evidence Generated at Build Time)

* Approximately 2,600 quality assurance hours returned per release cycle, reallocated to exception review and process design.

The Results

Platform clearance completed roughly seven months ahead of the original plan, because the review started from evidence that was already assembled and already current. Inspectors queried live records rather than requesting exports, and the inspection closed with no deviations raised against the validation programme.

The lasting change is cadence. Release frequency is now set by what the science is ready for rather than by how long a validation pack takes to write, and quality engineering hours moved off transcription and onto the exception review that actually needs a qualified human.

“The binder was never the problem. The problem was that the binder described a system we had already changed. Now the evidence is a by-product of the release, and when an inspector asks what the platform is doing, we answer in the present tense.”

Ingrid Salzmann

Vice President of Quality Assurance, Biotech Corp

Implementation Timeline

Biotech Corp moved from retrospective validation packs to continuous proofing across five phases.

Phase 1
GxP System Boundary Mapping
Zelar Trust identifies which platforms, pipelines and data stores fall inside the regulated boundary, and which qualification obligations attach to each.
Phase 2
Pipeline Instrumentation
Build and deployment pipelines are wired to emit installation and operational qualification records signed against the exact artefact released.
Phase 3
Continuous Performance Qualification
Operating envelopes move onto live monitoring, so performance qualification is proven constantly rather than reconstructed in a scheduled campaign.
Phase 4
Audit Trail Consolidation
21 CFR Part 11 trails are unified into one immutable, queryable record, removing the export-and-re-export cycle from every reviewer question.
Phase 5
Inspection Readiness Mode
Reviewers and inspectors query live validation state directly, with quality engineers signing exceptions rather than assembling documents.

Bring Continuous Audit Readiness to Your Organization

Understand where your governance, risk and compliance obligations stand today, and what continuous oversight would change. Our advisors will walk you through it.

Assess Your Cyber Governance Talk to a CISOaaS Advisor

Managed cyber governance for organizations that need continuous CISO leadership, Cyber GRC expertise and operational governance — without building the entire capability in-house.

CISO Governance Brief — practical insights on cyber governance, regulatory developments, risk, compliance and CISO leadership.